Format

Send to

Choose Destination
J Neuroimmunol. 2014 Feb 15;267(1-2):35-42. doi: 10.1016/j.jneuroim.2013.12.005. Epub 2013 Dec 12.

Treg depletion followed by intracerebral CpG-ODN injection induce brain tumor rejection.

Author information

1
Université d'Angers, Angers, France; INSERM, UMR892, Angers, France; CNRS, UMR 6299, Angers, France.
2
Université d'Angers, Angers, France; INSERM, UMR892, Angers, France.
3
Université d'Angers, Angers, France; INSERM, UMR892, Angers, France; CNRS, UMR 6299, Angers, France; CHU d'Angers, Laboratoire d'Immunologie et Allergologie, Angers, France.
4
Université d'Angers, Angers, France; INSERM, UMR892, Angers, France; CNRS, UMR 6299, Angers, France. Electronic address: dominique.couez@univ-angers.fr.

Abstract

Using brain lymphoma model, we demonstrate that immunotherapy combining Treg depletion (using anti-CD25 mAb PC61) followed by intracranial CpG-ODN administration induced tumor rejection in all treated mice and led to the establishment of a memory antitumor immune response in 60% of them. This protective effect was associated with a recruitment of NK cells and, to a lesser extent, of dendritic cells, B cells and T lymphocytes. NK cell depletion abolished the protective effect of the treatment, confirming a major role of NK cells in brain tumor elimination. Each treatment used alone failed to protect brain tumor bearing mice, revealing the therapeutic benefit of combining Treg depletion and local CpG-ODN injection.

KEYWORDS:

CNS tumor; CpG-ODN; NK cells; PAMP; PRR; Treg; pathogen recognition receptor; pathogen-associated molecular pattern

PMID:
24369298
DOI:
10.1016/j.jneuroim.2013.12.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center